Episode Details

Summary

In this Part 2 Best of ESMO 2025 episode of Melanoma Matters, hosts James Larkin and Sapna Patel cover the IO Biotech phase 3 trial, Checkmate 238 final results, the Safe Stop trial, the ECOG-ACRIN STAMP trial for Merkel cell carcinoma, and a promising TCR therapy for uveal melanoma.

Keywords

melanoma, cancer research, immunotherapy, clinical trials, ESMO, IO Biotech, Checkmate 238, Safe Stop trial, STAMP trial, uveal melanoma

Takeaways

The IO Biotech trial missed its primary endpoint for PFS.

Checkmate 238 confirmed previous findings on RFS and DMFS.

The Safe Stop trial suggests early discontinuation of therapy may be safe.

STAMP trial shows potential for adjuvant pembrolizumab in Merkel cell carcinoma.

Uveal melanoma TCR therapy shows promise.

Understanding subgroup analysis in interpreting trial results.

Patient management decisions should consider trial limitations and real-world implications.

Chapters

00:00 Travel Tips and Strategies

04:43 IO Biotech Phase 3 Trial Insights

12:00 Checkmate 238 Discussion

13:10 Navigating Publication Challenges

13:59 Checkmate 238 Results

15:58 Late Relapses and Follow-Up Strategies

17:57 Time of Day of Infusion

20:50 Safe Stop Trial: Evaluating Treatment Duration

33:12 STAMP Trial: Adjuvant Therapy for Merkel Cell Carcinoma

35:05 IMA-203 (Anzu-cel) trial in uveal melanoma